Nicotinic acetylcholine receptor subunit alpha-1 (nAChRα1 or CHRNA1)

Nicotinic acetylcholine receptor subunit alpha-1 (nAChRα1) is a protein encoded by the CHRNA1 gene and serves as a critical component of the pentameric muscle-type nicotinic acetylcholine receptor, primarily located at the neuromuscular junction[1][3][7]. The functional receptor is assembled from five subunits (two alpha-1, one beta-1, one delta, and either one gamma or one epsilon, depending on developmental stage)[1][2][3]. Upon binding acetylcholine, the receptor undergoes a conformational change that opens a cation-selective channel, permitting sodium and potassium flux, which leads to muscle fiber depolarization and contraction[3][7]. Mutations or autoimmune targeting of nAChRα1 can result in neuromuscular disorders such as myasthenia gravis and congenital myasthenic syndromes[3][5]. The receptor is a major clinical target for muscle relaxants used in anesthesia and for specific disease-modifying drugs in neuromuscular diseases[1][3][7].

Other names

CHRNA1Acetylcholine receptor alpha-1 subunitNeuromuscular acetylcholine receptor alpha-1 subunitAChR alpha-1 subunit

Agonists (e.g., acetylcholine, succinylcholine) bind to nAChRα1 to induce channel opening and muscle contraction Competitive antagonists (e.g., tubocurarine, pancuronium) block acetylcholine binding to inhibit depolarization and cause muscle relaxation/paralysis Non-depolarizing and depolarizing neuromuscular blocking agent mechanisms